Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$201.2M raised · US$22.15 a share · Jefferies +3 Dealers: Jefferies (co-lead), Goldman Sachs & Co. LLC (co-lead), Mizuho, Ladenburg Thalmann Use of proceeds: Working capital and general corporate purposes, including R&D for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials | Jan 23, 2026 |
| Warrant exercise of common stock warrants Closed: US$31.3M raised · US$3.5 a share Buyers: Richard Miller (559,073 shares purchased for $1,956,756) Insiders: CEO Richard Miller purchased 559,073 shares for $1,956,756 through early exercise of warrants | May 8, 2025 |
| Warrant exercise of common stock warrants Announced: about US$12.7M Buyers: Samlyn Capital (exercising warrants to purchase 3,633,978 shares of common stock) | Dec 18, 2024 |